DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Hiroyuki OgawaYasuhiro SakaiWataru NishioYusuke FujibayashiMegumi NishikuboYuki NishiokaShinya TaneYoshitaka KitamuraTamotsu SudoToshiko SakumaMasahiro YoshimuraPublished in: Thoracic cancer (2020)
Our results suggest that DLL3 expression-positive LCNEC may be better treated with other types of adjuvant chemotherapy, such as the anti-DLL3 therapies if these effects are confirmed by ongoing clinical research.